Treatment of high-risk neuroblastoma

Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trial...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
1. autor: Ki Woong Sung (Autor)
Format: Książka
Wydane: Korean Pediatric Society, 2012-04-01T00:00:00Z.
Hasła przedmiotowe:
Dostęp online:Connect to this object online.
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b9c0f05a9ebe4a61b9fae2a4f65f4c41
042 |a dc 
100 1 0 |a Ki Woong Sung  |e author 
245 0 0 |a Treatment of high-risk neuroblastoma 
260 |b Korean Pediatric Society,   |c 2012-04-01T00:00:00Z. 
500 |a 1738-1061 
500 |a 2092-7258 
500 |a 10.3345/kjp.2012.55.4.115 
520 |a Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trials, including tandem HDCT/autoSCT, high-dose 131I-metaiodobenzylguanidine treatment, and immunotherapy with NB specific antibody, have been undertaken and pilot studies have reported encouraging results. Nonetheless, about half of high-risk NB patients still experience treatment failure and have no realistic chance for cure with conventional treatment options alone after relapse. Therefore, a new modality of treatment is warranted for these patients. In recent years, several groups of investigators have examined the feasibility and effectiveness of reduced-intensity allogeneic stem cell transplantation (RI alloSCT) for the treatment of relapsed/progressed NB. Although a graft-versus-tumor effect has not yet been convincingly demonstrated in the setting of relapsed NB, the strategy of employing RI alloSCT has provided hope that treatment-related mortality will be reduced and a therapeutic benefit will emerge. However, alloSCT for NB is still investigational and there remain many issues to be elucidated in many areas. At present, alloSCT is reserved for specific clinical trials testing the immunomodulatory effect against NB. 
546 |a EN 
690 |a Neuroblastoma 
690 |a High-dose chemotherapy 
690 |a Allogeneic stem cell transplantation 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Korean Journal of Pediatrics, Vol 55, Iss 4, Pp 115-120 (2012) 
787 0 |n http://kjp.or.kr/upload/pdf/kjped-55-115.pdf 
787 0 |n https://doaj.org/toc/1738-1061 
787 0 |n https://doaj.org/toc/2092-7258 
856 4 1 |u https://doaj.org/article/b9c0f05a9ebe4a61b9fae2a4f65f4c41  |z Connect to this object online.